Faculty Opinions recommendation of Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.

Controlled Trial ◽

Small Cell ◽

Phase 2 ◽

Small Cell Lung ◽

Open Label ◽

Open Label Phase ◽

Previously Treated ◽

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

The Lancet ◽

10.1016/s0140-6736(16)00587-0 ◽

2016 ◽

Vol 387 (10030) ◽

pp. 1837-1846 ◽

Cited By ~ 1206

Author(s):

Louis Fehrenbacher ◽

Alexander Spira ◽

Marcus Ballinger ◽

Marcin Kowanetz ◽

Johan Vansteenkiste ◽

...

Keyword(s):

Lung Cancer ◽

Controlled Trial ◽

Small Cell ◽

Phase 2 ◽

Small Cell Lung ◽

Open Label ◽

Open Label Phase ◽

Previously Treated ◽

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

The Lancet ◽

10.1016/s0140-6736(16)32517-x ◽

2017 ◽

Vol 389 (10066) ◽

pp. 255-265 ◽

Cited By ~ 1731

Author(s):

Achim Rittmeyer ◽

Fabrice Barlesi ◽

Daniel Waterkamp ◽

Keunchil Park ◽

Fortunato Ciardiello ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Controlled Trial ◽

Small Cell ◽

Small Cell Lung ◽

Open Label ◽

Phase 3 ◽

Previously Treated ◽

Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial

The Lancet Oncology ◽

10.1016/s1470-2045(20)30013-9 ◽

2020 ◽

Vol 21 (4) ◽

pp. 581-592 ◽

Cited By ~ 14

Author(s):

Ursula Nestle ◽

Tanja Schimek-Jasch ◽

Stephanie Kremp ◽

Andrea Schaefer-Schuler ◽

Michael Mix ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Controlled Trial ◽

Locally Advanced ◽

Target Volume ◽

Small Cell ◽

Small Cell Lung ◽

Open Label ◽

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

The Lancet ◽

10.1016/s0140-6736(15)01281-7 ◽

2016 ◽

Vol 387 (10027) ◽

pp. 1540-1550 ◽

Cited By ~ 2708

Author(s):

Roy S Herbst ◽

Paul Baas ◽

Dong-Wan Kim ◽

Enriqueta Felip ◽

José L Pérez-Gracia ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Controlled Trial ◽

Small Cell ◽

Small Cell Lung ◽

Previously Treated ◽

Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial

The Lancet Oncology ◽

10.1016/s1470-2045(18)30896-9 ◽

2019 ◽

Vol 20 (4) ◽

pp. 494-503 ◽

Cited By ~ 110

Author(s):

David Ball ◽

G Tao Mai ◽

Shalini Vinod ◽

Scott Babington ◽

Jeremy Ruben ◽

...

Keyword(s):

Lung Cancer ◽

Controlled Trial ◽

Small Cell ◽

Stereotactic Ablative Radiotherapy ◽

Small Cell Lung ◽

Open Label ◽

Phase 3 ◽

Randomised Controlled ◽

Stage 1

Faculty Opinions recommendation of Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726044364.793539633 ◽

2017 ◽

Cited By ~ 2

Author(s):

Patrick Nana-Sinkam

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Controlled Trial ◽

Small Cell ◽

Small Cell Lung ◽

Previously Treated ◽

Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

The Lancet Oncology ◽

10.1016/s1470-2045(13)70586-2 ◽

2014 ◽

Vol 15 (2) ◽

pp. 143-155 ◽

Cited By ~ 496

Author(s):

Martin Reck ◽

Rolf Kaiser ◽

Anders Mellemgaard ◽

Jean-Yves Douillard ◽

Sergey Orlov ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Controlled Trial ◽

Small Cell ◽

Small Cell Lung ◽

Phase 3 ◽

Double Blind ◽

Previously Treated ◽

Faculty Opinions recommendation of Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718047126.793482089 ◽

2013 ◽

Author(s):

Thomas Stinchcombe

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Controlled Trial ◽

Small Cell ◽

Line Treatment ◽

Second Line ◽

Wild Type ◽

Small Cell Lung ◽

Daratumumab Plus Atezolizumab in Previously Treated Advanced or Metastatic Non‒Small-Cell Lung Cancer: Brief Report on a Randomized, Open-label, Phase 1b/2 Study (LUC2001 JNJ-54767414)

JTO Clinical and Research Reports ◽

10.1016/j.jtocrr.2020.100104 ◽

2020 ◽

pp. 100104

Author(s):

Rathi N. Pillai ◽

Suresh S. Ramalingam ◽

Meena Thayu ◽

Patricia Lorenzini ◽

Diana A. Alvarez Arias ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Open Label ◽

Open Label Phase ◽

Previously Treated ◽

Phase 1B

30MO ORIENT-3: A randomized, open-label, phase III study of sintilimab versus docetaxel in previously treated advanced/metastatic squamous non-small cell lung cancer (sqNSCLC)

Annals of Oncology ◽

10.1016/j.annonc.2020.10.517 ◽

2020 ◽

Vol 31 ◽

pp. S1428

Author(s):

Y. Shi ◽

L. Wu ◽

X. Yu ◽

P. Xing ◽

J. Zhou ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Open Label ◽

Open Label Phase ◽

Phase Iii Study ◽

Previously Treated